Real-World Evidence: CDER, Covis Flipped The Script For Leveraging Makena Observational Studies
Executive Summary
US FDA’s drugs center defended its use of observational studies and randomized trials in other populations to argue that evidence of Makena’s efficacy in preventing preterm birth is lacking; Covis’ expert said observational studies have little to contribute and trials in non-indicated populations are irrelevant.